Metagenomi(MGX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 · | | Metagenomi Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results Initiating IND-enabling activities for MGX-001 development candidate (DC) in hemophilia A; Achieved durable Factor VIII activity levels over twelve months in nonhuman primate (NHP) study On track for one to two DC nominations in 2025 from wave 1 Ionis collaboration programs focusing on cardiometabolic indications Novel adenine base editor (ABE) and ultra small SMART editing platform demonstrated highly ...